CLINICAL IMPLEMENTATION OF A NOVEL HIGH-THROUGHPUT SCREEN OF PRIMARY LEUKEMIA CELLS TO PERSONALIZE THERAPY FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

被引：0
|
作者：
Frattini, M. [1 ]
Shum, D. [1 ]
Heaney, M. [1 ]
Brentjens, R. [1 ]
Maslak, P. [1 ]
Jurcic, J. [1 ]
Djaballah, H. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0048
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [1] Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Customize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML).
    O'Dwyer, Kristen M.
    Shum, David
    Heaney, Mark
    Brentjens, Renier J.
    Maslak, Peter
    Jurcic, Joseph G.
    Djaballah, Hakim
    Frattini, Mark G.
    BLOOD, 2009, 114 (22) : 1042 - 1042
  • [2] A novel high-throughput screen of primary leukemia cells to personalize therapy for relapsed/refractory acute myeloid leukemia (AML): Proof of concept and clinical implementation of precision medicine
    Shum, David
    Santos, Ruth
    Heaney, Mark
    Brentjens, Renier
    Maslak, Peter
    Rosenblat, Todd
    Jurcic, Joseph
    Djaballah, Hakim
    Frattini, Mark G.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [3] Use of a high-throughput screen of primary leukemia cells to personalize therapy for relapsed/refractory AML: Proof of concept and clinical implementation of precision medicine.
    Shum, David
    Heaney, Mark
    Brentjens, Renier
    Maslak, Peter
    Jurcic, Joseph
    Djaballah, Hakim
    Frattini, Mark G.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [4] High-throughput mutation analysis in acute myeloid leukemia (AML)
    Dunlap, J.
    Corless, C. L.
    Fleming, W. H.
    Braziel, R.
    Leeborg, N.
    Gatter, K.
    Loriaux, M.
    Kelemen, K.
    Kovacsovics, T.
    Fan, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] COSTS OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) IN COLOMBIA
    Lasalvia, P.
    Gil, Rojas Y.
    Arciniegas Moreno, K.
    Saturnino, Ltm
    VALUE IN HEALTH, 2022, 25 (01) : S59 - S59
  • [6] Novel Therapeutics Targeting Acute Myeloid Leukemia (AML) Stem Cells Identified through High-Throughput Screening
    Iasenza, Isabella
    Safa, Safia
    Barabe, Frederic
    Cellot, Sonia
    Wilhelm, Brian T.
    Eppert, Kolja
    BLOOD, 2023, 142
  • [7] Salvage therapy for relapsed or refractory acute myeloid leukemia
    Mangan, James K.
    Luger, Selina M.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2011, 2 (02) : 73 - 82
  • [8] Novel strategies for relapsed and refractory acute myeloid leukemia
    Mato, Anthony R.
    Morgans, Alicia
    Luger, Selina M.
    CURRENT OPINION IN HEMATOLOGY, 2008, 15 (02) : 108 - 114
  • [9] OUTCOME OF PERSONALIZED THERAPY BASED ON HIGH-THROUGHPUT EX VIVO DRUG SCREENING IN PATIENTS WITH RELAPSED, CHEMOREFRACTORY ACUTE MYELOID LEUKEMIA (AML)
    Kontro, M.
    Pemovska, Tea
    Kulesskiy, E.
    Edgren, H.
    Eldfors, S.
    Elonen, E.
    Karjalainen, R.
    Majumder, M.
    Murumagi, A.
    Parsons, A.
    Aittokallio, T.
    Wennerberg, K.
    Kallioniemi, O.
    Porkka, K.
    HAEMATOLOGICA, 2013, 98 : 19 - 20
  • [10] High-Throughput Chemical Screen on Acute Myeloid Leukemia Stem Cells Identifies Novel Anti-LSC Compounds
    Iasenza, Isabella Angela
    Safa, Safia
    Barabe, Frederic
    Cellot, Sonia
    Wilhelm, Brian T.
    Eppert, Kolja
    BLOOD, 2021, 138 : 1871 - +
12345